NASDAQ:GHRS GH Research Q4 2023 Earnings Report $14.09 +0.04 (+0.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.71 -0.38 (-2.69%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast GH Research EPS ResultsActual EPS-$0.21Consensus EPS -$0.20Beat/MissMissed by -$0.01One Year Ago EPSN/AGH Research Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGH Research Announcement DetailsQuarterQ4 2023Date2/29/2024TimeN/AConference Call DateThursday, February 29, 2024Conference Call Time7:00AM ETUpcoming EarningsGH Research's Q2 2025 earnings is scheduled for Thursday, November 13, 2025Conference Call ResourcesPress Release (8-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(20-F) GH Research Earnings HeadlinesReviewing GH Research (NASDAQ:GHRS) & Abeona Therapeutics (NASDAQ:ABEO)September 3 at 4:07 AM | americanbankingnews.comGH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression TrialSeptember 2, 2025 | uk.finance.yahoo.comWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."September 6 at 2:00 AM | Altimetry (Ad)Brokerages Set GH Research PLC (NASDAQ:GHRS) PT at $32.00September 1, 2025 | americanbankingnews.comGH Research (GHRS) to Release Earnings on TuesdayAugust 31, 2025 | americanbankingnews.comGH Research PLC to Engage Investors at Cantor Global Healthcare ConferenceAugust 29, 2025 | tipranks.comSee More GH Research Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email. Email Address About GH ResearchGH Research (NASDAQ:GHRS) Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health. The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring. Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline. GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.Written by Jeffrey Neal JohnsonView GH Research ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
